Article Information
PubMed
Print ISSN
Online ISSN
History
- Received March 11, 2022
- Revision received July 8, 2022
- Accepted August 15, 2022
- Published online January 4, 2023.
Article Versions
- Earlier version (December 8, 2022 - 14:38).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2023 by The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Al-Hassan M. Mustafa and
- Oliver H. Krämer
- Lynette Daws, ASSOCIATE EDITOR
- Address correspondence to:
Oliver H. Krämer, Department of Toxicology, University Medical Center, Obere Zahlbacher Str. 67, 55131 Mainz, Germany. E-mail: okraemer{at}uni-mainz.de
Statistics from Altmetric.com
Article usage
In this issue
Jump to section
- Article
- Visual Overview
- Abstract
- I. Introduction
- II. Relevance of Janus Kinases for Tumorigenesis
- III. Histone Deacetylases Are Valid Pharmacological Targets in Janus Kinase Mutant Tumor Cells
- IV. Chemically Coupled Multitargeting Drugs
- V. Targeting Aberrant Janus Kinase Signaling by Proteolysis Targeting Chimeras and Histone Deacetylase Inhibitors
- VI. Clinical Trials to Assess the Safety and Efficacy of Combined Pharmacological Targeting of Janus Kinases and Histone Deacetylases
- VII. Summary
- Authorship Contributions
- Footnotes
- Abbreviations
- References
- Figures & Data
- Info & Metrics
- eLetters
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement